Compare Ascendis Pharma A/S (ASND) vs iShares iBoxx $ High Yield Corporate Bond ETF (HYG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ascendis Pharma A/S vs iShares iBoxx $ High Yield Corporate Bond ETF — how do they compare? Ascendis Pharma A/S trades at $263.66 (market cap $17.74B), while iShares iBoxx $ High Yield Corporate Bond ETF trades at $79.65. The key difference: Ascendis Pharma A/S is trading nearer its 52-week high, iShares iBoxx $ High Yield Corporate Bond ETF nearer its low. Which is the better fit depends on your goals.
| ASND | HYG | |
|---|---|---|
Market Cap | $17.74B | — |
Sector | Health | Fixed Income |
52-Week High | $277.18 | $81.32 |
52-Week Low | $163.32 | $78.72 |
Enterprise Value | $18.11B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
HYG (iShares iBoxx High Yield Corporate Bond ETF) trades at $79.71, down 0.05% with a bearish technical signal from moving averages. The ETF faces pressure from elevated put volume and broader bond market uncertainty as investors weigh potential Federal Reserve rate hikes. Recent dividend payments of $0.37-$0.42 per share provide income support, but technical indicators show weak momentum with RSI readings in neutral territory.
High-yield bond ETFs face headwinds from rising rate expectations and inflation concerns, though demand for yield remains strong. The bearish technical setup suggests near-term pressure, while institutional bearish positioning indicates cautious sentiment. Income-focused investors may find value in the dividend yield, but rate sensitivity remains a key risk factor.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About iShares iBoxx $ High Yield Corporate Bond ETF
HYG is the world's largest high-yield bond ETF, tracking the Markit iBoxx USD Liquid High Yield Index. It provides liquid exposure to non-investment grade corporate debt, with 2026 top holdings including Cloud Software Group and Medline.
Read more on HYG →
